PT - JOURNAL ARTICLE AU - Roopa Kalyanaraman Marcello AU - Johanna Dolle AU - Sheila Grami AU - Richard Adule AU - Zeyu Li AU - Kathleen Tatem AU - Chinyere Anyaogu AU - Stephen Apfelroth AU - Raji Ayinla AU - Noella Boma AU - Terence Brady AU - Braulio F. Cosme-Thormann AU - Roseann Costarella AU - Kenra Ford AU - Kecia Gaither AU - Jessica Jacobson AU - Marc Kanter AU - Stuart Kessler AU - Ross B. Kristal AU - Joseph J. Lieber AU - Vikramjit Mukherjee AU - Vincent Rizzo AU - Madden Rowell AU - David Stevens AU - Elana Sydney AU - Andrew Wallach AU - Dave A. Chokshi AU - Nichola Davis AU - New York City Health + Hospitals COVID-19 Population Health Data Team TI - Characteristics and Outcomes of COVID-19 Patients in New York City’s Public Hospital System AID - 10.1101/2020.05.29.20086645 DP - 2020 Jan 01 TA - medRxiv PG - 2020.05.29.20086645 4099 - http://medrxiv.org/content/early/2020/06/23/2020.05.29.20086645.short 4100 - http://medrxiv.org/content/early/2020/06/23/2020.05.29.20086645.full AB - Background New York City (NYC) has borne the greatest burden of COVID-19 in the United States, but information about characteristics and outcomes of racially/ethnically diverse individuals tested and hospitalized for COVID-19 remains limited. In this case series, we describe characteristics and outcomes of patients tested for and hospitalized with COVID-19 in New York City’s public hospital system.Methods We reviewed the electronic health records of all patients who received a SARS-CoV-2 test between March 5 and April 9, 2020, with follow up through April 16, 2020. The primary outcomes were a positive test, hospitalization, and death. Demographics and comorbidities were also assessed.Results 22254 patients were tested for SARS-CoV-2. 13442 (61%) were positive; among those, the median age was 52.7 years (interquartile range [IQR] 39.5-64.5), 7481 (56%) were male, 3518 (26%) were Black, and 4593 (34%) were Hispanic. Nearly half (4669, 46%) had at least one chronic disease (27% diabetes, 30% hypertension, and 21% cardiovascular disease). Of those testing positive, 6248 (46%) were hospitalized. The median age was 61.6 years (IQR 49.7-72.9); 3851 (62%) were male, 1950 (31%) were Black, and 2102 (34%) were Hispanic. More than half (3269, 53%) had at least one chronic disease (33% diabetes, 37% hypertension, 24% cardiovascular disease, 11% chronic kidney disease). 1724 (28%) hospitalized patients died. The median age was 71.0 years (IQR 60.0, 80.9); 1087 (63%) were male, 506 (29%) were Black, and 528 (31%) were Hispanic. Chronic diseases were common (35% diabetes, 37% hypertension, 28% cardiovascular disease, 15% chronic kidney disease). Male sex, older age, diabetes, cardiac history, and chronic kidney disease were significantly associated with testing positive, hospitalization, and death. Racial/ethnic disparities were observed across all outcomes.Conclusions and Relevance This is the largest and most racially/ethnically diverse case series of patients tested and hospitalized for COVID-19 in the United States to date. Our findings highlight disparities in outcomes that can inform prevention and testing recommendations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding/Support: This study was funded in part by the Clinical & Translational Science Award grant #UL1TR001445 from the National Institutes of Health. Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Biomedical Research Alliance of New York Institutional Review Board. Waivers of informed consent and of the Health Information Portability and Privacy Act were granted due to the retrospective nature of the study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are from NYC Health + Hospitals' EHR system.